SCHEMBL2676271

SCHEMBL2676271

O=C(O)c1c(CNCC2CCCC2)n(-c2ccccc2)c(=O)c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESRRA P11474 2/20 0.46
PDE7A Q13946 1/20 0.42
WNK1 Q9H4A3 1/20 0.41
MAPK1 P28482 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 2/20 0.39
TP53 P04637 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
BCL2L1 Q07817 1/20 0.39
MCL1 Q07820 1/20 0.39
ALDH1A1 P00352 4/20 0.38
IDO1 P14902 1/20 0.38
HTR3E A5X5Y0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2677075 0.95 MAPK1 (0.42) ESRRAPDE7AWNK1MAPK1NPSR1
SCHEMBL2675405 0.85 KDM4E (0.46) PDE7AMAPK1NPSR1L3MBTL1NPC1
SCHEMBL2676570 0.84 KDM4E (0.47) PDE7AMAPK1NPSR1L3MBTL1NPC1
SCHEMBL2676530 0.82 KDM4E (0.43) MAPK1NPSR1L3MBTL1NPC1RAB9A
SCHEMBL1717345 0.82 KCNK3 (0.47) LMNAALDH1A1HPGD
SCHEMBL2675552 0.82 MAPK1 (0.43) PDE7AMAPK1NPSR1L3MBTL1KMT2A
SCHEMBL2675896 0.82 MAPK1 (0.45) PDE7AMAPK1NPSR1L3MBTL1NPC1
SCHEMBL2677820 0.79 MAPK1 (0.47) MAPK1NPSR1L3MBTL1NPC1RAB9A
SCHEMBL2676255 0.79 KDM4E (0.45) MAPK1NPSR1L3MBTL1KMT2AMEN1
SCHEMBL2676286 0.79 MAPK1 (0.42) MAPK1NPSR1L3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 ESRRA 1654/4885PDE7A 771/4885WNK1 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.